AMRZ earnings analysis
What we found in AMRZ's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Amrize's Q2 2026 results showed a substantial sequential recovery, with revenue of $3.494 billion and diluted EPS of $0.88 versus $2.18 billion and a $0.21 loss in Q1 2026. Revenue and EPS also improved versus Q2 2025, although the supplied earnings data shows EPS was below the $0.99 consensus estimate. The filing continues to identify ineffective disclosure controls and an unresolved material weakness as significant governance and reporting risks, while providing no quantitative guidance.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue rebounded strongly
- Revenue was $3.494 billion, up approximately 60.3% from $2.18 billion in Q1 2026 and 8.5% from $3.22 billion in Q2 2025.
- EPS recovered year over year
- Diluted EPS was $0.88 versus a loss of $0.21 in Q1 2026 and $0.78 in Q2 2025, indicating a $1.09 sequential improvement and $0.10 year-over-year increase.
- Share repurchases began
- Amrize repurchased 3,759,896 shares during Q2 2026. The program had a $1.0 billion authorization and 15,059,621 shares remaining as of June 30, 2026.
- Market risk profile unchanged
- Management stated that there were no material changes to market risks from those disclosed in the 2025 Form 10-K for the six months ended June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material weakness remains unresolved
- Disclosure controls were not effective as of June 30, 2026 because of a previously reported material weakness related to insufficient accounting and supervisory personnel with appropriate U.S. GAAP technical experience and training.
- Remediation remains incomplete
- The company said the material weakness will not be considered remediated until enhanced controls operate for a sufficient period and testing concludes they are effective; the filing provides no completed remediation date.
- No material risk-factor improvement
- The filing states there were no material changes to risk factors disclosed in the 2025 Form 10-K, limiting evidence of any reduction in the company's existing risk profile.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.88
What they said about what is next.
The supplied 10-Q text does not provide quantitative revenue or EPS guidance. Recent news references a guidance cut, but that information is outside the filing text.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Amrize Ltd (AMRZ) reported Q1 2026 with revenue of $2.18 billion, reflecting a 4.7% increase from $2.08 billion year-over-year. However, net loss widened to $118 million compared to $87 million in the prior year. The…
- 10-K · February 18, 2026
- Amrize completed its June 23, 2025 spin-off from Holcim and operates as a North American building-solutions company organized into two reportable segments (Building Materials and Building Envelope). The filing…
- 10-Q · August 7, 2025
- Amrize Ltd's Q2 2025 results reflect a decline in revenue and earnings compared to the previous quarter and prior year, attributing challenges to operational adjustments following its separation from Holcim. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AMRZ makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever